blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3939583

EP3939583 - IMPROVEMENTS IN CANCER TREATMENT WITH ISOFLAVONOIDS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  25.11.2022
Database last updated on 20.09.2024
FormerThe application has been published
Status updated on  17.12.2021
Most recent event   Tooltip25.11.2022Application deemed to be withdrawnpublished on 28.12.2022  [2022/52]
Applicant(s)For all designated states
Noxopharm Limited
PO Box 824
Turramurra, New South Wales 2074 / AU
[2022/03]
Inventor(s)01 / KELLY, Graham
Turramurra, 2074 / AU
 [2022/03]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2022/03]
Application number, filing date21176052.528.07.2016
[2022/03]
Priority number, dateUS201662318946P06.04.2016         Original published format: US 201662318946 P
[2022/03]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3939583
Date:19.01.2022
Language:EN
[2022/03]
Search report(s)(Supplementary) European search report - dispatched on:EP06.12.2021
ClassificationIPC:A61K31/353, A61K47/44, A61K9/00, A61K9/02, A61P35/00
[2022/03]
CPC:
A61K9/02 (EP,KR,US); A61K9/0031 (EP,KR,US); A61K31/353 (EP,KR,US);
A61K47/12 (KR,US); A61K47/44 (EP,US); A61K9/0034 (EP,KR,US);
A61P35/00 (EP,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/03]
TitleGerman:VERBESSERUNGEN IN DER KREBSBEHANDLUNG MIT ISOFLAVONOIDEN[2022/03]
English:IMPROVEMENTS IN CANCER TREATMENT WITH ISOFLAVONOIDS[2022/03]
French:AMÉLIORATIONS DANS LE TRAITEMENT DU CANCER AVEC DES ISOFLAVONOÏDES[2022/03]
Examination procedure20.07.2022Application deemed to be withdrawn, date of legal effect  [2022/52]
09.08.2022Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time  [2022/52]
Parent application(s)   TooltipEP16897482.2  / EP3439651
Fees paidRenewal fee
26.05.2021Renewal fee patent year 03
26.05.2021Renewal fee patent year 04
26.05.2021Renewal fee patent year 05
26.05.2021Renewal fee patent year 06
Penalty fee
Additional fee for renewal fee
31.07.202207   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]KR20110004525  ;
 [XDI]WO9808503  (NOVOGEN RES PTY LTD [AU], et al) [XD] 1-4,7-9,11,12 * pages 2-4; compounds 1-10 * * page 6, lines 6-20 * * page 9, lines 11-16 * * page 11, lines 15-17 * * claims 2, 4 * [I] 5,6,10;
 [X]WO2004009035  (CHILDRENS HOSP MEDICAL CENTER [US], et al) [X] 1-3,7-9,11,12 * page 11, paragraph [0061] ** page 26, paragraph [0145] *;
 [XI]WO2004030662  (NOVOGEN RES PTY LTD [AU], et al) [X] 1-4,7-9,11,12 * page 19, line 16 - page 21, line l * * page 27, lines 1-3 * * page 30, lines 1-5 * * page 31, lines 23-28 * * page 36, lines 18-23 * * example 2 * * claims 1, 6-9, 12-13 * [I] 5,6,10;
 [XI]US2007036834  (PAULETTI GIOVANNI M [US], et al) [X] 1-3,5-7,9,11,12 * page 19; example 3 * [I] 4-6,8,10;
 [A]  - LIPP M ET AL, "Review of cocoa butter and alternative fats for use in chocolate-Part A. Compositional data", FOOD CHEMISTRY, ELSEVIER LTD, NL, (19980101), vol. 62, no. 1, doi:10.1016/S0308-8146(97)00160-X, ISSN 0308-8146, pages 73 - 97, XP002212469 [A] 1-12 * abstract * * page 76; table 4 *

DOI:   http://dx.doi.org/10.1016/S0308-8146(97)00160-X
 [X]  - DATABASE WPI, 0, Derwent World Patents Index, vol. 2012, no. 04, Database accession no. 2011-B25102, XP002794198 & KR20110004525 A 20110114 (UNIV DONG EUI IND ACADEMIC COOP FOUND) [X] 1-3,7-9,11,12 * abstract *
by applicantWO9808503
 WO2005049008
    - ALVERO ABROSSI PBROWN DLEISER AKELLY MRUTHERFORD THUSBAND AJMOR G, "Phenoxodiol - a chemosensitizer in the midst of cancer chemoresistance", US Oncology, (20080000), vol. 24, pages 39 - 41
    - LIU HQ LCHENG X et al., "UDP-glucuronosyltransferase 1 A determinates intracellular accumulation and anti-cancer effect of (3-lapachone in human colon cancer cells", PLoS One, (20150000), vol. 10, page 11705
    - PANT SBURNS HABENDELL JCKURKJIAN CJONES SFMORENO OKUHN JGMCMEEKIN SINFANTE JR., "A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid cancers", Invest New Drugs, (20140000), vol. 32, doi:10.1007/s10637-013-9949-4, pages 87 - 93, XP035906180

DOI:   http://dx.doi.org/10.1007/s10637-013-9949-4
    - PIAO MMORI DSATOH T et al., "Inhibition of endothelial cell proliferation, in vitro angiogenesis, and the down-regulation of cell adhesion-related genes by genistein. Combined with a cDNA microarray analysis", Endothelium, (20060000), vol. 13, no. 4, pages 249 - 66
    - ADJAKLY MNGOLLO MDAGDEMIR AJUDES GPAJON AKARSLI-CEPPIOGLU SPENAULT-LLORCA FBOITEUX JPBIGNON YJGUY L, "Prostate cancer: the main risk and protective factors - epigenetic modifications", Ann Endoncrinol (Paris, (20150000), vol. 76, pages 25 - 41
    - KAZI ADANIEL KGSMITH DM et al., "Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein.", Biochem Pharmacol, (20030000), vol. 66, no. 6, pages 965 - 76
    - GUY LVEDRINE NURPI-SARDA MGIL-IZGUIERDO AAI-MAHARIK NBOITEAUX JPSCALBERT AREMESY CBOTTING NPMANACH C., "Orally administered isoflavones are present as glucosides in the human prostate", J Nutr, (20080000), vol. 60, pages 461 - 8
    - ZHANG YHENDRICH SMURPHY PA., "Glucuronides are the main isoflavone metabolites in women", J Nutr, (20030000), vol. 133, pages 399 - 404
    - KING CDRIOS GRGREEN MDTEPHLY TR, "UDP-glucuronosyltransferases", Curr Drug Metab, (20000000), vol. 1, doi:10.2174/1389200003339171, pages 143 - 161, XP001121074

DOI:   http://dx.doi.org/10.2174/1389200003339171
    - GUILLEMETTE C., "Pharmacogenomics of human UDP-glucuronosyltransferase enzymes", Pharmacogenomics J, (20030000), vol. 3, pages 136 - 158
    - MARUO YIWAI MMORI ASATO HTAKEUCHI Y., "Polymorphism of UDP-glucuronosyltransferase and drug metabolism", Curr Drug Metab, (20050000), vol. 6, pages 91 - 99
    - WU BKULKARNI KBASU SZHANG SHU M., "First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics", J Pharmaceutical Sci, (20110000), vol. 100, pages 3655 - 3681
    - HOWES JBDE SOUZA PLWEST LHUANG LJHOWES LG, "Pharmacokinetics of phenoxodiol, a novel isoflavone, following intravenous administration to patients with advanced cancer", BMC Clin Pharmacol., (20110203), vol. 11, doi:10.1186/1472-6904-11-1, page 1, XP021087936

DOI:   http://dx.doi.org/10.1186/1472-6904-11-1
    - MACHIN GAHALPER JPKNOWLES DM., "Cytochemically demonstrable b-glucuronidase activity in normal and neoplastic lymphoid cells", Blood, (19800000), vol. 56, pages 1111 - 9
    - PETERS WHMKOCK LNAGENGAST FMKREMERS PG., "Biotransformation enzymes in human intestine. Critical low levels in the colon?", Gut, (19910000), vol. 32, pages 408 - 412
    - BASU NKCIOTTI MHWANG MSKOLE LMITRA PSCHO JWOWENS IS, "Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake", J Biol Chem, (20040000), vol. 279, pages 1429 - 1441
    - FOTOPOULOU CVERGOTE IMAINWARING PBIDZINSKI MVERMORKEN JBGHAMANDE SAHARNETT PDEL PRETE SAGREEN JASPACZYNSKI M, "Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the Phase III OVATURE multicentre randomized study", Ann Oncol, (20140000), vol. 25, pages 160 - 165
    - BROWN DHEATON AHUSBAND A, "Idronoxil", Drugs Fut, (20080000), vol. 33, no. 10, pages 844 - 860
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.